BioSpace News Archive

Business

FIU researcher named Fellow of the National Academy of Inventors

Florida International University Distinguished Professor Madhavan Nair has been named a Fellow of the National Academy of Inventors.

December 9, 2019
·
2 min read
Deals

Quest Diagnostics Prices $800 Million of Senior Notes

Quest Diagnostics Incorporated announced the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest Diagnostics’ shelf registration statement.

December 9, 2019
·
2 min read
Business

GEDmatch Partners With Genomics Firm Verogen

GEDmatch, a pioneer in consumer genealogy, announced that it has joined with forensic genomics firm Verogen, Inc. in a move that allows the company to ensure ongoing privacy protections and enhance the customer experience for users of its website.

December 9, 2019
·
3 min read
Drug Development

Amphivena Reports Data on Phase 1 Study of AMV564 at Ash Annual Meeting

Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented at the American Society of Hematology annual meeting data from a Phase 1 study of its bivalent T cell engager clinical candidate, AMV564.

December 9, 2019
·
4 min read
Drug Development

Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Data support novel approach to develop a best-in-class, durable medicine for people living with hemoglobinopathies

December 9, 2019
·
4 min read
Drug Development

bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18

December 9, 2019
·
14 min read
Drug Development

Astex Pharmaceuticals Presents Topline Data from the ASCERTAIN Phase 3 Study of its Novel, Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.

The study achieved its primary objective of decitabine systemic exposure equivalence between oral ASTX727 and IV decitabine with an oral/IV ratio of approximately 99%

December 9, 2019
·
8 min read
Drug Development

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups

December 9, 2019
·
11 min read
Business

Bioelectronic medicine shows potential to treat pulmonary hypertension

A team led by Stavros Zanos, MD, PhD, assistant professor at the Feinstein Institutes for Medical Research, has published an overview of how bioelectronic medicine may be used to treat pulmonary arterial hypertension in the Springer Nature journal, Bioelectronic Medicine.

December 9, 2019
·
2 min read
Drug Development

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209.

December 9, 2019
·
3 min read